Yazar "Göksu, Sema Sezgin" için listeleme
-
Assessment of prognostic factors and adjuvant treatment modalities in adult head and neck soft tissue sarcoma patients treated with upfront surgery
Akagündüz, Baran; Akın Telli, Tuğba; Göksu, Sema Sezgin; Yıldırım, Hasan Çağrı; Özer, Muhammet; Göktaş Aydın, Sabin; Özyurt, Neslihan; Karacin, Cengiz; Paydaş, Semra; Doğan, Mutlu (Cureus Inc., 2021)ObjectivesHead and neck soft tissue sarcomas (HNSTSs) are a heterogeneous group of rare tumors. Surgical resection with negative margins remains the standard primary treatment for patients with HNSTS. The role of chemotherapy ... -
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group
Gürbüz, Mustafa; Kutlu, Yasin; Akkuş, Erman; Köksoy, Elif Berna; Köse, Naziyet; Öven, Bala Başak; Oyan Uluç, Başak; Demiray, Atike Gökçen; Erdem, Dilek; Demir, Bilgin; Turhal, Nazım Serdar; Üskent, Necdet; Akbaş, Sinem; Selçukbiricik, Fatih; İnal, Ali; Bilici, Ahmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Ünal, Çağlar; Hizal, Mutlu; Şendur, Mehmet Ali Nahit; Korkmaz, Mustafa; Karadurmuş, Nuri; Ertürk, İsmail; Göksu, Sema Sezgin; Tatlı, Ali Murat; Güven, Deniz Can; Kılıçkap, Saadettin; Paksoy, Nail; Aydıner, Adnan; Yeşil Çınkır, Havva; Özkul, Özlem; Öztürk, Akın; Ballı, Sevinç; Kemal, Yasemin; Erdoğan, Atike Pınar; Er, Özlem; Yumuk, Perran Fulden; Demirkazık, Ahmet (Springer, 2022)Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In ... -
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Karacin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah (BioMed Central Ltd, 2023)Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which ... -
Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group
Akagündüz, Baran; Akın Telli, Tuğba; Yıldırım, Hasan Çağrı; Göksu, Sema Sezgin; Demir, Nazan; Hafızoğlu, Emre; Özer, Muhammet; Çevik, Gökçen Tuğba; Sakin, Abdullah; Göktaş Aydın, Sabin; Şengül Samancı, Nilay; Özyurt, Neslihan; Atçı, Muhammed Mustafa; Ayhan, Murat; Turan, Merve; Sarıyar, Nisanur; Karaçin, Cengiz; Kılıçkap, Saadettin; Paydaş, Semra; Doğan, Mutlu (Akad Doktorlar Yayinevi, 2021)Retroperitoneal sarcomas (RPS) account for approximately 15% of all soft tissue sarcomas (STS) and encompass a heterogeneous group of tumors with limited multimodality treatment options. Surgical resection with negative ... -
Pazopanib in metastatic soft tissue sarcoma (STS): Results of a multi-institutional observational study
Bilici, Ahmet; Koca, Sinan; Karaağaç, Mustafa; Eraslan, Emrah; Ocak, Birol; Göktaş Aydın, Sabin; Göksu, Sema Sezgin; Paydaş, Semra; Derin, Sümeyye; Ergün, Yakup; Yekegündüz, Emre; Erol, Cihan; Tataroğlu Özyükseler, Deniz; Demiray, Atike Gökçen; Karaca, Mustafa; Güç, Zeynep Gülsüm; Menekşe, Serkan; Çınkır, Havva Yeşil; Gümüşay, Özge; Sakin, Abdullah (Lippincott Williams and Wilkins, 2022)... -
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: A retrospective Turkish oncology group (TOG) study
Bilici, Ahmet; Koca, Sinan; Karaağaç, Mustafa; Aydın Göktaş, Sabin; Eraslan, Emrah; Kaplan, Muhammed Ali; Ocak, Birol; Göksu, Sema Sezgin; Paydaş, Semra; Akgül, Fahri; Derin, Sümeyye; Ergün, Yakup (Springer, 2023)Aim: Description of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS). Patients and methods: This multicenter study is based on retrospective ...